Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 2/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | SENP2 | Q9HC62 | 3/20 | 0.31 |
| ▸ | SENP1 | Q9P0U3 | 3/20 | 0.31 |
| ▸ | SUMO2 | P61956 | 2/20 | 0.31 |
| ▸ | SUMO1 | P63165 | 2/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.31 |
| ▸ | SENP3 | Q9H4L4 | 2/20 | 0.31 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16553161 | 1.00 | CYP2D6 (0.35) | CYP2D6TSHRSMN1; SMN2TTRKDM4E | |
| SCHEMBL28875258 | 0.98 | CYP2D6 (0.34) | CYP2D6TSHRSMN1; SMN2TTRKDM4E | |
| SCHEMBL5272789 | 0.93 | CYP2D6 (0.35) | CYP2D6TSHRSMN1; SMN2TTRKDM4E | |
| SCHEMBL7783772 | 0.93 | CYP2D6 (0.35) | CYP2D6TSHRSMN1; SMN2TTRKDM4E | |
| SCHEMBL28576715 | 0.91 | CYP2D6 (0.34) | CYP2D6TSHRSMN1; SMN2TTRKDM4E | |
| SCHEMBL4878318 | 0.91 | TSHR (0.38) | CYP2D6TSHRSMN1; SMN2TTRKDM4E | |
| SCHEMBL2524546 | 0.77 | TSHR (0.48) | CYP2D6TSHRSMN1; SMN2TTRKDM4E | |
| SCHEMBL2842391 | 0.76 | NR1I2 (0.39) | TSHRTTRPOLBTDP1PSD | |
| SCHEMBL29908011 | 0.76 | NR1I2 (0.39) | TSHRTTRPOLBTDP1PSD | |
| Hydrochloric Acid SCHEMBL11755878 | 0.75 | TSHR (0.46) | CYP2D6TSHRSMN1; SMN2TTRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4433487-A1 | CYTARABINE-AMINO ACID BASED PRODRUG FOR THE TREATMENT OF CANCER | BioSight Ltd. (IL) | 2024-09-25 | — | — | EP | claimed |
| EP-4288062-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | Epalex Corporation (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023089617-A1 | CYTARABINE-AMINO ACID BASED PRODRUG FOR THE TREATMENT OF CANCER | BIOSIGHT LTD. (IL) | 2023-05-25 | — | — | WO | claimed |
| WO-2022169520-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION (US) | 2022-08-11 | — | — | WO | claimed |
| US-20250313564-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-10-09 | — | — | US | disclosed |
| US-20250000862-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING ENDOMETRIOSIS, UTERINE FIBROIDS, POLYCYSTIC OVARY SYNDROME OR ADENOMYOSIS | ABBVIE INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4471032-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| CN-118715224-A | Acid salt or crystal form of nitrogen-containing fused ring derivative inhibitor, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-4433487-A1 | CYTARABINE-AMINO ACID BASED PRODRUG FOR THE TREATMENT OF CANCER | BioSight Ltd. (IL) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023089617-A1 | CYTARABINE-AMINO ACID BASED PRODRUG FOR THE TREATMENT OF CANCER | BIOSIGHT LTD. (IL) | 2023-05-25 | — | — | WO | disclosed |
| US-11478490-B1 | Fospropofol formulations | EPALEX CORPORATION (US) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478490-B1 | Fospropofol formulations | FOS, PFAS, FOSB | CYP2D6 40/4885TSHR 2607/4885SMN1; SMN2 1000/4885 |
| US-20250313564-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | NR5A1, HSD17B11, CYP17A1 | CYP2D6 3240/4885TSHR 678/4885SMN1; SMN2 4839/4885 |
| US-20250000862-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING ENDOMETRIOSIS, UTERINE FIBROIDS, POLYCYSTIC OVARY SYNDROME OR ADENOMYOSIS | GNRHR, LPXN, LHCGR | CYP2D6 2482/4885TSHR 663/4885SMN1; SMN2 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.